D-1332-2020 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1332-2020 was initiated by Teva Pharmaceuticals USA on Jun 2, 2020 and is designated Class II. Reason for recall: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level The recall status is terminated (terminated Apr 12, 2024). Affected quantity: a) 15,329 bottles and b) 137 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 1, 2020
Initiation Date
Jun 2, 2020
Termination Date
Apr 12, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 15,329 bottles and b) 137 bottles

Product description

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 62037-577-01) and b) 1000 (NDC 62037-577-10), Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa, Distributed by: Actavis Pharma, Inc., Parsippany, NJ

Reason for recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Distribution pattern

Product was distributed throughout the United States, including Puerto Rico.

Code information

a) 1333338M, exp. date 08/2020, 1333339A, exp. date 08/2020; b) 1354471A, exp. date 02/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1332-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1332-2020. Report a data issue: hello@regdatalab.com.